Cue Biopharma Granted U.S. Patent #11,370,821 T-cell modulatory multimeric polypeptides and methods of use thereof
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5531&f=G&l=50&d=PTXT&p=111&S1=20220628&OS=20220628&RS=20220628"> https://patft.uspto.gov/netacgi/nph-Parser?Sect1=
‘Cue Health rode Covid-19 to an NBA deal and a $3 billion valuation. Now it faces layoffs and a rocky future’ -STAT Article
https://www.statnews.com/2022/06/27/cue-health-covid-test-stock-investigation/
Morgan Stanley Maintains Equal-Weight on Cue Health, Lowers Price Target to $10
Morgan Stanley maintains Cue Health (NASDAQ:HLTH) with a Equal-Weight and lowers the price target from $11 to $10.
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell
• Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
Cue Health Makes De Novo Submission To FDA For Full Clearance Of Its Molecular COVID-19 Test
SAN DIEGO, May 2, 2022 /PRNewswire/ -- Cue Health ("Cue") (NASDAQ:HLTH) today became the first company to submit to the U.S. Food and Drug Administration (FDA) for full clearance of its molecular
Stocks That Hit 52-Week Lows On Friday
During Friday's morning session, 234 stocks hit new 52-week lows.
Morgan Stanley Maintains Equal-Weight on Cue Health, Lowers Price Target to $11
Morgan Stanley analyst Tejas Savant maintains Cue Health (NASDAQ:HLTH) with a Equal-Weight and lowers the price target from $12 to $11.
Earnings Scheduled For March 29, 2022
Companies Reporting Before The Bell
• 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.